123 related articles for article (PubMed ID: 6684577)
1. Pharmacological properties of platelet strips.
Yamakado T; Nishikawa M; Azuma H; Hidaka H
Eur J Pharmacol; 1983 Aug; 91(4):441-7. PubMed ID: 6684577
[TBL] [Abstract][Full Text] [Related]
2. The platelet strip. I. A low-fibrin contractile model of thrombin-activated platelets.
Salganicoff L; Loughnane MH; Sevy RW; Russo M
Am J Physiol; 1985 Sep; 249(3 Pt 1):C279-87. PubMed ID: 3898863
[TBL] [Abstract][Full Text] [Related]
3. Some characteristics of mouse platelet aggregation and a comparison of the activity of a range of compounds in mouse and human platelet-rich plasma in vitro.
Nunn B
Thromb Haemost; 1981 Feb; 45(1):1-5. PubMed ID: 7245119
[TBL] [Abstract][Full Text] [Related]
4. The effect of pyridoxal-5-phosphate on the inhibition of platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation in human platelets.
Zahavi M; Zahavi J; Kakkar VV
Life Sci; 1984 Oct; 35(14):1497-503. PubMed ID: 6090838
[TBL] [Abstract][Full Text] [Related]
5. [Effect of aggregation inducers and inhibitors on the functional properties and the ultrastructure of platelets].
Lakin KM; Makarow WA; Mular AG
Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):849-52. PubMed ID: 94877
[TBL] [Abstract][Full Text] [Related]
6. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
Zahavi M; Zahavi J; Kakkar VV
Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ADP-induced responses in human platelets by agents elevating the cyclic AMP level: comparison of aggregation and shape change.
Steen VM; Holmsen H
Thromb Haemost; 1984 Dec; 52(3):333-5. PubMed ID: 6099615
[TBL] [Abstract][Full Text] [Related]
8. Effect of prostaglandins and drotaverine on ADP-induced platelet aggregation.
Losonczy H; Nagy I; Gregus Z
Acta Med Acad Sci Hung; 1974; 31(3-4):157-63. PubMed ID: 4469713
[No Abstract] [Full Text] [Related]
9. Role of myosin phosphorylation in contractility of a platelet aggregate.
Bromberg ME; Sevy RW; Daniel JL; Salganicoff L
Am J Physiol; 1985 Sep; 249(3 Pt 1):C297-303. PubMed ID: 2994487
[TBL] [Abstract][Full Text] [Related]
10. ADP induced depolarization of human platelet membrane potential.
Wencel-Drake JD; Feinberg H
Thromb Haemost; 1985 Feb; 53(1):75-9. PubMed ID: 4039475
[TBL] [Abstract][Full Text] [Related]
11. [Effect of prostaglandins E1 and E2 on thrombocyte form and aggregation].
Antonikov IM; Alekseev OV; Chernukh AM
Biull Eksp Biol Med; 1982 Apr; 93(4):11-3. PubMed ID: 6952942
[TBL] [Abstract][Full Text] [Related]
12. Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors.
Cusack NJ; Hourani SM
Br J Pharmacol; 1982 May; 76(1):221-7. PubMed ID: 6282375
[TBL] [Abstract][Full Text] [Related]
13. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
Weber AA; Reimann S; Schrör K
Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
Khanna V; Armstrong PC; Warner TD; Curzen N
Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
[TBL] [Abstract][Full Text] [Related]
15. Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline.
Michal F; Motamed M
Br J Pharmacol; 1976 Feb; 56(2):209-18. PubMed ID: 1252669
[TBL] [Abstract][Full Text] [Related]
16. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
Lam SC; Guccione MA; Packham MA; Mustard JF
Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of cytochalasin B on platelet release, aggregation and contractility: evidence against a contractile mechanism for the release of platelet granular contents.
Kirkpatrick JP; McIntire LV; Moake JL; Cimo PL
Thromb Haemost; 1980 Feb; 42(5):1483-9. PubMed ID: 6892735
[TBL] [Abstract][Full Text] [Related]
18. Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha.
Krauss AH; Woodward DF; Gibson LL; Protzman CE; Williams LS; Burk RM; Gac TS; Roof MB; Abbas F; Marshall K; Senior J
Br J Pharmacol; 1996 Mar; 117(6):1171-80. PubMed ID: 8882612
[TBL] [Abstract][Full Text] [Related]
19. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
Brammer JP; Maguire MH
Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
[TBL] [Abstract][Full Text] [Related]
20. Effects of a polyoxyethylene detergent (Brij 58) on platelet aggregation, release and clotting activity.
Barton PG
Biochim Biophys Acta; 1978 Feb; 539(1):98-113. PubMed ID: 623796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
